Drug Profile
Research programme: therapeutic hepatitis B vaccine - Vaxine
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Vaxine
- Class Hepatitis B vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hepatitis B
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-B in Australia (Injection)
- 23 Oct 2013 The therapeutic vaccine is still in preclinical development for the treatment of Hepatitis B in Australia.
- 27 Nov 2006 Preclinical trials in Hepatitis B treatment in Australia (Injection)